Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has introduced a new antibody optimisation platform called arYla, to accelerate antibody optimisation, with the goal of generating superior therapeutic and diagnostic candidates faster and more cost- effectively than is currently possible.
Subscribe to our email newsletter
arYla is expected to be used to optimise a range of properties critical to the successful development of a therapeutic or diagnostic antibody.
The arYla technology results from the combined technology platforms of MorphoSys and recently acquired Sloning BioTechnology.
MorphoSys CEO Simon Moroney said that arYla gives them a proprietary means of optimising antibody properties, which they expect to lead to better products, both therapeutics and diagnostics.
"We intend to apply the technology in our own programs and within existing as well as new partnerships, and are already seeing considerable interest in the pharmaceutical industry," Moroney said.
MorphoSys claimed that with its arYla technology, the company combines more than 15 years of experience in design and selection of therapeutic antibodies with the library synthesis capabilities acquired with Sloning in October 2010.
Additionally, arYla brings significant advantages to antibody optimisation especially in terms of speed and flexibility.
MorphoSys added that the new technology enables individualised antibody libraries to be made with speed and precision and that arYla will be used to make diverse, customised sub-libraries based on an existing lead compound, incorporating many millions of pre-defined variations at precisely determined sites within the antibody structure.